Foscarbidopa
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
Reply to: "Alkaline phosphatases as a potential source of variability in foslevodopa response: Muscles beyond pharmacokinetics".
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: July 15, 2026
Alkaline Phosphatases as a Potential Source of Variability in Foslevodopa Response: Muscles beyond Pharmacokinetics.
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: June 21, 2026
Continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: A clinical workflow from 50 consecutive patients at a single U.S. center.
Journal: Clinical parkinsonism & related disorders
Published: June 17, 2026
The current status of pump therapy options for advanced Parkinson's disease in Hungary
Journal: Ideggyogyaszati szemle
Published: June 03, 2026
Do We Need to Monitor B-Vitamins and Homocysteine During Initiation of Foslevodopa/Foscarbidopa Therapy?
Journal: Movement disorders : official journal of the Movement Disorder Society
Published: May 05, 2026
Foslevodopa+foscarbidopa for advanced Parkinson disease.
Journal: Australian prescriber
Published: April 23, 2026
Real-world implementation of continuous subcutaneous foslevodopa/foscarbidopa in advanced Parkinson's disease: first clinical experience from the Middle East.
Journal: Therapeutic advances in neurological disorders
Published: April 10, 2026
Beyond "Advanced": proposing Fluctuation-Dominant Parkinson's disease as a functional alternative to enable timely device-aided therapy.
Journal: Journal of neural transmission (Vienna, Austria : 1996)
Published: April 04, 2026
Neuropsychiatric Adverse Events Associated With Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Clinical Practice: A Multicenter Study.
Journal: European journal of neurology
Published: March 30, 2026
Opicapone as Add-On Therapy to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: Clinical Improvement and Wearable Sensor-Based Gait Analysis.
Journal: Brain sciences
Published: March 21, 2026
Effect of subcutaneous foslevodopa/foscarbidopa therapy on non-motor symptoms in advanced PD patients.
Journal: Journal of neurology
Published: March 11, 2026
Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.
Journal: Neurology and therapy
Published: February 27, 2026
Last Updated: 09/26/2026